OKYO Pharma (OKYO) Stock Price, News & Analysis

Company Overview

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $1.10 to $1.15
• 50-Day Range: $1.01 to $1.29
• 52-Week Range: $0.81 to $1.90
• Volume: 109,111 shs
• Average Volume: 268,051 shs
• Market Capitalization: $37.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

OKYO Pharma Stock Analysis - MarketRank™

OKYO Pharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 505th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

OKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

OKYO Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for OKYO Pharma are expected to remain at ($0.17) per share in the coming year.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.36% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently increased by 59.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OKYO Pharma does not currently pay a dividend.

Dividend Growth

OKYO Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.36% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently increased by 59.77%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.01

News Sentiment

OKYO Pharma has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for OKYO Pharma this week, compared to 1 article on an average week.

Search Interest

1 people have searched for OKYO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.97% of the stock of OKYO Pharma is held by institutions.

OKYO Stock Analysis - Frequently Asked Questions

How have OKYO shares performed this year?

OKYO Pharma's stock was trading at $1.1499 at the start of the year. Since then, OKYO shares have decreased by 3.0% and is now trading at $1.1150.
View the best growth stocks for 2025 here.

When did OKYO Pharma IPO?

OKYO Pharma (OKYO) raised $2 million in an IPO on Tuesday, May 17th 2022. The company issued 625,000 shares at $4.00 per share.

How do I buy shares of OKYO Pharma?

Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OKYO Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Meta Platforms (META), Intel (INTC), NVIDIA (NVDA), C3.ai (AI), Bristol-Myers Squibb (BMY), Energy Transfer (ET) and Ford Motor (F).

Company Calendar

• Today: 2/21/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OKYO
• CUSIP: N/A
• CIK: 1849296
• Web: www.okyopharma.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +527.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.28
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.20) per share
• Price / Book: -5.58

Miscellaneous

• Outstanding Shares: 33,840,000
• Free Float: 20,146,000
• Market Cap: $37.73 million
• Optionable: Not Optionable
• Beta: -0.27